logo
Getting On The Shelf Is Only Half The Sale

Getting On The Shelf Is Only Half The Sale

Forbes17-07-2025
Joel Goldstein is the President of Mr. Checkout Distributors.
You finally did it. Your product made it to the shelf. It's sitting upright, facing front, ready to meet its future. But here's the truth: Most brands learn too late that getting on the shelf is only half the sale.
Retail isn't a destination—it's a dynamic living, breathing environment where products compete not just on price or packaging, but on presence. Once you're stocked, the clock starts ticking. The product must move. And if it doesn't, you're not on the shelf—you're on borrowed time.
Too many brands believe that placement is success. They celebrate the purchase order (PO) and forget the sell-through. But retail is ruthless. If your product sits too long, it becomes background noise. It fades. And eventually, it's replaced.
Your job doesn't end when the delivery arrives—it begins. This is where the smart brands separate themselves. The ones who show up after the sale—who check inventory, ask questions and support the retailer, not just invoice them.
We saw this firsthand with a small, family-owned gourmet popcorn company we worked with—handmade, five bold flavors in eye-popping bags. They landed a dozen independent retailers in their first month. But instead of moving on to chase more, they circled back. They walked the aisles. They trained the clerks. They set up tasting stations on Saturday afternoons. Customers got to try it. Staff got to love it. Retailers saw it fly off the shelves. That same product, placed and left alone, would've stalled. Not because it wasn't good, but because nothing sells itself anymore. Not even popcorn.
Movement matters. Retailers may like your story, but they love results. You must be more than charming—you must be proven. When your product moves, you buy yourself more time, more space and more trust.
Don't confuse marketing with motion. Ads are great. Instagram posts help. But a strategic hand-sell from a trusted store owner will always outperform a paid placement. If you want a real edge, give retailers the tools to sell for you. Arm them with talking points. Give them signage. Let them feel like part of your story. Because when they believe in your product, they don't just stock it—they sell it. Actively. With pride. With personal conviction. And that kind of support can't be bought. It's built.
There's also the hard truth: If your product isn't moving, you need to know. Not months later, when the PO's dry. Now. A retailer who gives honest feedback is worth more than any distributor who gives you scale without insight. Take their input seriously. Change what isn't working. Iterate quickly. Retail rewards the responsive.
Getting on the shelf is your product's first day of school. The world won't adjust to it—it must learn to stand out, perform and be picked. And your job as the brand is to stay close, pay attention and guide that growth.
Because no matter how beautiful your packaging or how unique your ingredients, if your product doesn't move, it doesn't stay. And in retail, shelf space isn't owned—it's earned again and again.
So get on the shelf, yes. But don't stop there. Turn your product into a presence. Turn your placement into pull. Be seen. Be tried. Be talked about. Because half a sale isn't enough. Not when the next product is always waiting.
Forbes Business Development Council is an invitation-only community for sales and biz dev executives. Do I qualify?
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth
Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth

Yahoo

time26 minutes ago

  • Yahoo

Cell and Gene Therapy Supply Chain Software Market Report 2025-2035: 170+ Software Solutions Providers Fueling Fragmented Cell & Gene Therapy Supply Chain Market Growth

The global cell and gene therapy supply chain software market is set to expand from USD 0.27 billion in 2025 to USD 1.32 billion by 2035, at a CAGR of 15.2%. Driven by demand for advanced therapies, the market is enhanced by cloud-based technologies and key players like Azenta Life Sciences and Lonza. Cell and Gene Therapy Supply Chain Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts to 2035: Distribution by Process Component, Type of Software, Mode of Deployment, Scale of Operation, Type of End-user and Key Geographical Regions" report has been added to offering. The global cell and gene therapy supply chain software market is estimated to grow from USD 0.27 billion in 2025, to USD 1.32 billion by 2035, at a CAGR of 15.2% during the forecast period, to 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: GROWTH AND TRENDS Advanced therapies are gradually evolving the face of modern healthcare. These new regenerative and immunotherapy modalities have the potential to improve treatment outcomes by providing viable therapy solutions to patients who currently have limited or no treatment options. Given the nature of these treatment modalities, these therapies have a limited lifespan, even when shipped under temperature-controlled conditions. It becomes increasingly important to track the source of the sample from the time of its collection, current location and manufacturing processes. Following this fact, for the commercial success of such therapies, an effective manufacturing platform and a robust supply chain model are imperative. It is worth mentioning that a sustainable supply chain enables further reductions in the cost of goods and, in turn, prices of such therapies. The supply chain for innovative therapies is complicated from the outset and given the interdependencies amongst multiple stakeholders, it becomes challenging to manage and streamline the overall process. This has reinforced the need for bespoke and integrated software solutions to help innovators manage the critical intricacies of the supply chain. These software systems have huge potential to manage a multitude of events, maintain the chain of identity and custody, and enable stakeholders to optimize the complex supply chains, while also ensuring compliance with global regulatory standards. Driven by the growing demand for cell and gene therapies and the availability of easy to integrate software solutions to manage cell and gene therapy supply chain, this market is expected to grow significantly in the foreseen future. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: KEY INSIGHTS The report delves into the current state of the cell and gene therapy supply chain software market and identifies potential growth opportunities within the industry. Some key findings from the report include: Presently, close to 175 cell and gene therapy supply chain software solutions are available in the market; of these, 22% are laboratory information management systems. Over 20% of the cell and gene therapy supply chain software solutions can be deployed both on-premises and over the cloud, offering flexibility as well as contact-less options for the end-users. The current market landscape of cell and gene therapy supply chain software providers is fragmented, featuring the presence of both new entrants and established players; majority of these players are based in the US. The growing interest in this domain is evident from the rise in partnership activity; in fact, 40 partnership deals related to cell and gene therapy supply chain software were inked in 2023. Several investors, having realized the opportunities associated within supply chain management software domain, have invested USD 3 billion across various funding rounds in the past 10 years. Driven by the increasing pace of innovation and partnership activity, the market for cell and gene therapy supply chain software is poised to witness steady growth in the foreseeable future. The cell and gene therapy supply chain software market is anticipated to grow at a CAGR of 15.2%, till 2035; North America is expected to capture the majority share (over 45%) of the market by 2035. CELL AND GENE THERAPY SUPPLY CHAIN SOFTWARE MARKET: RESEARCH COVERAGE Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy supply chain software market, focusing on key market segments, including process component, type of software, mode of deployment, scale of operation and key geographical regions. Market Landscape: A comprehensive evaluation of cell and gene therapy supply chain software solutions, considering various parameters, such as type of software, key features, application area, mode of deployment, scale of operation, regulatory guidelines followed and type of end-user. Additionally, it includes a detailed list of developers providing cell and gene therapy supply chain software solutions, along with analysis based on various parameters, such as year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe, Asia-Pacific, and rest of the world) and most active players based on the number of software solutions offered. Company Competitiveness Analysis: A comprehensive competitive analysis of cell and gene therapy supply chain software solution providers, examining factors, such as developer strength and product portfolio strength. Company Profiles: In-depth profiles of key cell and gene therapy supply chain software solution providers, focusing on company overviews, software solutions portfolio, financial information, recent developments and an informed future outlook. Funding and Investment Analysis: A detailed evaluation of the investments made in this domain, encompassing seed funding, venture capital, debt financing, grants / awards, capital raised from IPOs and subsequent offerings. Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, covering acquisitions, platform utilization agreements, service alliances, platform integration agreements, product development agreements, service agreements and other agreements. Platform Utilization Agreements in Supply Chain Software Solutions Market: An in-depth analysis of the platform utilization agreements inked in this domain since 2019, providing information on the different types of software utilized by end-users in the cell and gene therapy supply chain. Stakeholder Need Analysis: A qualitative evaluation of the current and future needs of various stakeholders in the cell and gene therapy supply chain, including patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators. This section provides a summary of the distinct needs of these stakeholders and presents our opinion (drawn from historical and current trends) on the impact of these needs on the supply chain and how the industry is preparing to cater to these needs. Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth. Sample Players in the Cell and Gene Therapy Supply Chain Software Market, Profiled in the Report Include: Azenta Life Sciences Biocair BioLife Solutions CareDx Cryoport Lonza NMDP BioTherapies TraceLink TrakCel Veeva Systems Emerson LabVantage Solutions Marken MasterControl QuickSTAT Siemens Stafa Cellular Therapy Steiner STEMSOFT Software TECHNIDATA Thermo Fisher Scientific KEY QUESTIONS ANSWERED IN THIS REPORT How many companies are currently engaged in this market? Which are the leading companies in this market? What kind of partnership models are commonly adopted by industry stakeholders? What are the factors that are likely to influence the evolution of this market? What is the current and future market size? What is the CAGR of this market? How is the current and future market opportunity likely to be distributed across key market segments? REASONS TO BUY THIS REPORT The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants. Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies. The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects. ADDITIONAL BENEFITS Complimentary PPT Insights Packs Complimentary Excel Data Packs for all Analytical Modules in the Report 10% Free Content Customization Detailed Report Walkthrough Session with Research Team For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cell and Gene Therapy Supply Chain CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

Bank of Canada widely expected to hold key rate steady amid trade uncertainty
Bank of Canada widely expected to hold key rate steady amid trade uncertainty

Yahoo

time26 minutes ago

  • Yahoo

Bank of Canada widely expected to hold key rate steady amid trade uncertainty

OTTAWA — Avery Shenfeld doesn't think the Bank of Canada will cut its benchmark interest rate at its decision on Wednesday, but if it does, he said it will be a "pleasant surprise." "There's always a chance that they'll surprise with the rate cut," the chief economist of CIBC said. "But I'm not holding out that much hope." Most economists are also expecting the Bank of Canada will hold its policy rate steady at 2.75 per cent for a third consecutive decision later this week. As of Friday afternoon, financial markets were placing odds of a quarter-point rate cut on Wednesday at just seven per cent, according to LSEG Data & Analytics. Stubbornness on the inflation front and surprise strength in the labour market have quashed arguments for further easing since the central bank's June decision. The Canadian economy gained an unexpected 83,000 jobs in June, Statistics Canada reported earlier this month, driving the unemployment rate lower for the first time since January. A few days later, StatCan reported annual inflation ticked up to 1.9 per cent last month while the Bank of Canada's closely watched core inflation figures held stubbornly around three per cent. "Overall, sticky inflation readings, a weakening but relatively resilient economic backdrop and prospects for larger fiscal spending are reasons why we do not expect the BoC will cut again in this cycle," RBC economists Claire Fan and Abbey Xu wrote in a note Friday. But Shenfeld's call for a lower policy rate — CIBC expects two more quarter-point drops before the Bank of Canada is done — isn't based on what's happened in the economy, it's about what's on the horizon. Outside of the June jobs jump, the labour market is still broadly weak with the unemployment rate at 6.9 per cent, Shenfeld noted. He also expects Canada's tariff dispute with the United States led to an economic contraction in the second quarter of the year. All told, there's enough "slack" building in the economy to take steam out of inflation in the months to come, Shenfeld said. The Bank of Canada's own second-quarter business outlook survey released last week suggests that many firms are opting to absorb higher costs from tariffs, rather than pass them on to consumers who may be reining in spending amid economic uncertainty. Shenfeld said that's a sign that tariff impacts "won't extend into a more persistent inflation issue." He said that once the central bank gains enough confidence that any tariff-induced inflation pressures will be short-lived, monetary policymakers should feel confident enough to lower interest rates. "I think at this point they know enough to rule out the worst-case scenario on trade," Shenfeld said. Bank of Canada governor Tiff Macklem has explicitly said monetary policymakers are being less forward-looking than usual in the trade war. The central bank didn't publish a traditional forecast for the economy in its April monetary policy report, instead offering two scenarios for how tariffs could hit the economy. Jimmy Jean, chief economist at Desjardins, said he believes the Bank of Canada will have gathered enough clarity on the trade front to return to formal forecasts in this week's MPR. "The uncertainty is there for everyone to recognize. But there's a point where you've got to sort of, stick your neck out and make the proper caveats," Jean said. Tariff deadlines continue to hover over the Bank of Canada's head — U.S. President Donald Trump has threatened to levy tariffs of 35 per cent on Canadian imports starting Friday if a trade deal isn't reached before then, though CUSMA-compliant goods are expected to be exempt from the duties. Some forecasters, including RBC, expect the Bank of Canada is already done rate cuts and will turn the job of stimulating the economy through the trade war over to federal and provincial governments. While Jean also believes the central bank will opt to hold rates again on Wednesday, he said the bank's next decision in September is an "open possibility" for a cut. Trump's sectoral tariffs targetting Canada's steel, aluminum and copper industries are of particular concern for Ontario and Quebec, Jean said. If those tariffs are sustained, he argued more rate cuts from the Bank of Canada will be warranted to cushion the economic hit. In addition to some sector-specific relief, the federal government has moved in recent months to ramp up Canada's defence and infrastructure funding — spending that could offer fiscal, rather than monetary, support for the economy. But Jean said Desjardins is expecting that lift to come over the ensuing years, not months, opening a window for the Bank of Canada to lower rates in the near-term. "We think, despite those measures being in the pipeline, the Bank of Canada will still in September have a valid reason to cut interest rates," he said. This report by The Canadian Press was first published July 28, 2025. Craig Lord, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Asimily Adds Enhanced IoT Password Management and Device Patching to Its Comprehensive Security Platform
Asimily Adds Enhanced IoT Password Management and Device Patching to Its Comprehensive Security Platform

Yahoo

time26 minutes ago

  • Yahoo

Asimily Adds Enhanced IoT Password Management and Device Patching to Its Comprehensive Security Platform

SUNNYVALE, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Asimily, the only complete IoT, OT, and IoMT Risk Mitigation Platform, today announced the release of several new innovative features designed to help organizations across all industries efficiently secure and manage IoT devices while continuing down its path of cybersecurity innovation. These features are: IoT Password Management significantly simplifies the execution of password best practices across devices from multiple manufacturers. IoT Patching offers a 200% increase in supported manufacturers whose devices can now be automatically updated by Asimily. An intuitive new user interface designed for speed and efficiency, particularly for busy security and IT teams. 'Organizations with device fleets have always struggled to keep them updated. Unlike servers and operating systems, there is no streamlined process owned by the software manufacturer for IoT. This has always forced organizations to devote significant time and money to this essential line of defense,' said Shankar Somasundaram, CEO of Asimily. 'With our new IoT Management module and its Password Management and Patching capabilities, devices get automatically and fully updated faster with far less time and effort, helping prevent successful attacks from establishing a foothold within a company's networks.' IoT devices, such as printers, IP cameras, teleconference devices and network access points, are increasingly common targets for cyberattacks. Securing and managing IoT fleets requires the right software, processes, and skilled personnel to balance operational functionality and security. These features join the Asimily platform as crucial components, purpose-built to address the unique challenges associated with IoT Unauthorized Access with IoT Password Management Under the IoT Management module, Asimily has added IoT Password Management. This feature helps organizations enforce stronger credential policies and reduce the risk of unauthorized access to critical IoT infrastructure. It makes organizational adherence to best practices – strong passwords, no re-use – much easier while still allowing devices to operate with minimal interruption. Asimily's IoT Patching and IoT Password Management work together to prevent unauthorized access, allowing patching to be performed with a click, according to a schedule, or automatically. Increased Manufacturer Support for IoT Management Asimily has expanded its manufacturer support for IoT Management. This broader support ensures that even more devices can be automatically patched with Asimily, enabling better security for organizations. As businesses across industries continue to adopt new IoT devices, the expansion of this feature enables organizations to confidently lean into IoT while scaling security practices as their fleet grows. Since the initial launch of IoT Patching in March, 2025, the number of supported vendors has doubled, making thousands more customer devices easily updatable. Asimily is on track to increase the number of supported vendors by 400% within a year, dramatically expanding its direct-patching coverage. New User Interface Asimily recently refreshed its user interface to simplify adoption, organize crucial features around common workflows, reduce friction to accomplish critical risk mitigation tasks, and support a best-in-class user experience. Driven by extensive research and testing, the new interface reinforces Asimily's commitment to innovation and enables users to take decisive action across IoT, OT, and IoMT infrastructure. Ready to Strengthen Your IoT Security? See how Asimily's new capabilities make device management faster, safer, and easier than ever here. About Asimily Asimily has built an industry-leading risk management platform that secures IoT devices for organizations in healthcare, manufacturing, higher education, government, life sciences, retail, and finance. With the most extensive knowledge base of IoT and security protocols, Asimily inventories and classifies every device across organizations, both connected and standalone. Because risk assessment—and threats—are not a static target, Asimily monitors organizations' devices, detects anomalous behavior, and alerts operators to remediate any identified anomalies. With secure IoT devices and equipment, Asimily customers know their business-critical devices and data are safe. For more information on Asimily, visit Asimily ContactKyle Petersonkyle@ A photo accompanying this announcement is available at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store